Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Oxford AcademicOpen Access

From Genes to Care: The expanding therapeutic horizon in rare genetic obesities

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSarah ChalopinEGEmilie GuillonPFPauline Faucher

Discussion

Loading...

Member takes

Overview

This review explores targeted treatments for rare genetic obesities affecting appetite regulation, highlighting emerging therapies and precision medicine implications.

Key Points

  • Targeted therapies improve appetite regulation in genetic obesities, focusing on biological mechanisms.
  • Recent pharmacological treatments like setmelanotide and semaglutide enhance satiety and reduce hyperphagia.
  • Understanding the leptin–melanocortin axis could lead to more effective interventions for debilitating obesity.
  • The need for multidisciplinary care remains critical for long-term safety and efficacy of new obesity treatments.

Cite This Study

Chalopin et al. (2025) studied this question.

synapsesocial.com/papers/68e25559d6d66a53c247513fhttps://doi.org/10.1093/obendo/wjaf007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 52020 · 286 citations